Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patent for what?
Is this a patent for DR-70? If so, why do you think it will result in revenues or profits for Radient?
Thanks in advance.
It only took 4 months to WHAT?
Is this your evidence for an RXPC buyout? I fail to see it.
Is this your evidence that the Rosen class action is without merit? I fail to see it.
In fact, I fail to see the relevance of what you just posted.
I would love to know what you are talking about. thanks in advance.
Post your evidence of this RXPC merger. I see no evidence that RXPC is being merged with, bought out, acquired, or accumulated. I see no reason to believe any entity would want to own this company. I think the debt is toxic and their only product is a financial failure. I see no reason for anyone to resurrect this failed biotech.
Other than a metaphysical belief that RXPC will rise from the ashes, where is the evidence of a buyout or merger?
Thanks in advance.
A good summer for longs? Explain why.
I see nothing that indicates this will be a good summer for RXPC longs. In fact, I expect bankruptcy filings before November, because Radient cannot afford to go to court, regardless of whether they think they are guilty or not.
But, let's hear your logic. How will Radient find the money to pay a lawyer for representation in a jury trial?
Read Radient's PR from January 18 2011 - they removed it from their website but you can still find it on marketwire.
Then read the Mayo Clinic's public response.
I think a jury is going to read those and find that Radient's PR was intentionally deceiving.
Regardless -- I question why anyone would celebrate the lack of volume in a stock and I don't understand why anyone would offer congratulations to owners of a pinksheet stock that hasn't filed financials since 2011, has 4.5 billion shares outstanding, is trading at .0001, and does not have an operational bricks-and-mortar office. But, we all have different investment strategies.
to clarify:
Investor A visited the office and looked for himself.
Investor B called a dentist down the hall and spoke to a receptionist.
Investor B's due diligence is superior to Investor A's due diligence because..... why?
Thanks in advance.
Radient removed the January 18 2011 PR from its website, but you can still find it here:
http://www.marketwire.com/press-release/radient-pharmaceuticals-announces-progress-potential-completion-date-its-onko-surer-nyse-amex-rpc-1381430.htm
The problematic lines, IMO:
"...announced today progress on its clinical study with Mayo Clinic ("Mayo") for the validation of the Company's US FDA-cleared Onko-Sure® in vitro diagnostic (IVD) cancer test..."
AND
"Based on recent advancements, RPC anticipates it will complete the clinical trial with Mayo in the first quarter of 2011."
These are problematic because there was no "clinical study with Mayo" - there was a clinical study in which Mayo tested some blood samples with CEA, sold those samples to Radient, and Radient tersted the same samples with DR-70.
It wasn't a clinical trial, but specifically, it wasn't a "clinical trial with Mayo."
It's also questionable the way MacLellan stated "To have internationally recognized leaders in oncology take such great interest in Onko-Sure® is a testament to the importance of the test." Is he implying that the Mayo Clinic is the internationally recognized leader that took interest in onko-sure? Because they did NOT.
It all boils down to whether a jury thinks Radient intended to deceive. I think the jury will find Radient guilty, especially since the Mayo Clinic felt the need to issue a subsequent press release stating:
" Mayo is not engaged in clinical studies with Radient and does not have a partnership agreement with Radient. "
http://newsblog.mayoclinic.org/2011/03/07/mayo-response-to-radient-article/
Congrats long investors?
Congrats for what? I see nothing to celebrate. Radient the corporation will have to appear in court in November. They have no money for lawyers.
And exactly what evidence do you have of a "creeping takeover group?" I don't see any evidence whatsoever that there is any kind of takeover group, creeping or otherwise. I strongly question the existence of a takeover group. Anyone wanting to market, sell, and/or develop DR-70 could simply license the test and avoid the costs of paying the debt, paying the $900,000 in unpaid bills from January 2012, bringing SEC filings up to date, and appearing in court.
Please share your DD and explain why you think there is a takeover group. Why is this takeover group delaying the takeover while interest accrues on the lender debt at 24%? That makes no sense to me. Thanks in advance.
Finally, News: Rosen class action
http://globenewswire.com/news-release/2013/05/21/548807/10033632/en/Rosen-Law-Firm-Achieves-Significant-Victory-Against-Radient-Pharmaceuticals-Corp-in-Securities-Class-Action-RXPC.html
My opinion: Ariura skated, nice job. Radient is penniless so a judgement against them would yield nothing -- they can just file BK to avoid any kind of judgement. Since they have no money for lawyers, perhaps this will end Radient before November?
But BK by Radient would not free MacLellan from judgement.
runncoach, yes I remember -- Jade made AMDL profitable one quarter, and it wasn't from selling DR-70 in China!
The military confiscated the plant and a couple of floods set back the other JPI plant.... and the Jade decided they'd had enough of the yankee overlords.
The share count might not have exceeded 25 million if Jade hadn't mutinied. MacLellan might have been able to find private investors and never needed loan sharks. But we'll never know.
all pniksheet subpenny stocks are manipulated. That is the only reason to buy them. Nobody can say they bought RXPC on fundamentals.
Message board banter won't affect the PPS. A hype PR could make it rise a few tics. Nothing else will make it rise, IMO.
I don't expect another 8K again, ever, unless this company does the decent thing and files for bankruptcy. I don't think GCDx is going to get funding for DR-70. But, for the sake of argument, let's say GCDx tries to find financing, and we see an 8K flurry similar to the 8K flurry from last year regarding GCDx. Would $300,000 make a difference for Radient? I think not. Forget the lender debt.... they still have $900,000 in unpaid operational bills. MacLellan certainly did not pay those bills out of his own pocket, and Radient has had no significant income of any kind since they reported that $900,000 debt. SRL had already paid for their DR-70 kits.
Who lives near LA? I wish someone would visit the Radient office and report what they find. Now THAT would be real DD.
The race to develop a screener.
This is the most current news I can find about CellSearch, the JnJ Veridex device that I think makes onko-sure obsolete:
http://www.xconomy.com/boston/2013/04/16/mgh-veridex-device-enters-challenging-arena-in-tumor-cell-testing/
JnJ has the muscle and the funding to push through a device and get the global medical community to USE it. And we all know that biotech is NOT about saving the world or curing cancer -- it is about making money.
However, this article implies that CellSearch won't get to market for 5-10 years. That probably means 7-15 years.
Is that enough time for someone to try and get the new formulation of DR-70 to market?
I assume you all know that the old formulation of DR-70 contains an ingredient that is no longer available. This was first disclosed in 2008 by Rudd:
http://www.ruddreport.com/Research/amdl/amd_3Q08_11.htm
"Although the Company has obtained approval from the USFDA to market the then current formulation of DR-70® it has been determined that one of the key components of the DR-70® -- the anti-fibrinogen-HRP is limited in supply and additional quantities cannot be purchased. "
For anyone who doesn't know who Rudd is: he was the "analyst" paid by AMDL to "write" about the company. He preceded Garza. Most of the spikes in the historical PPS of this stock between 2004 and 2008 coincided with the release of Rudd's "reports."
If you're interested, here is a piece of analysis I like to share: The previous CEO, Dreher, always found private investors to buy stock in private placements to get funding -- he never took out loans. MacLellan, in contrast, could NOT find private investors, and borrowed money instead. Dreher never had loans to repay, while MacLellan never repaid a loan.
Do you see why I love to follow this company?
Investigation? of what?
I have seen the SEC overlook the pinksheets more often than not. And I'm not sure what people are referring to when they call for an "investigation." The SEC is definitely not going to "investigate" what is being said on message boards about a .0001 pinksheet stock that hasn't filed since 2011.
If you reported something material about the company -- for example, if someone handed Mac a bogus buyout LOI and Mac decided to run with it in what I lovingly refer to as "the pinkie buyout scam"-- the SEC might investigate THAT. However, I have seen that particular scam run successfully with no SEC interaction.
I think there are some RPC shareholders who have no idea what the pinksheets are, and were dragged down here only because they refused to sell for a loss as the company imploded. There is a valuable lesson to be learned here, for those few.
Of course, there are many shareholders who saw the volume created by the SRL PR, and are hoping to sell at .0003 for a fast dollar. Those people know the pinksheet game. They are not "longs." Some of them say dishonest things on message boards, but that is the game, in their minds -- some people think that lying on these boards is a victimless crime. We all recognize this. I loathe it, but, I can't stop it.
However, I think this kind of lying and deception is a waste of time. The only thing that will get the PPS back to .0003 is another piece of "news." I don't see where that will come from, myself, but then I didn't see the SRL "news" coming.
If you want some entertainment, read the Yahoo board. You have to filter through the angry bagholder who is extracting some sort of revenge against the world by flooding the board with bashing.... We call him "the all-caps basher." But there are two stalwart shareholders who have concocted a bizarre buyout rumor in which 19 separate Provista private shareholders are handing over Provista to the Radient lenders in exchange for a secret takeover of Radient. It's great reading.
Typo: DR-70 was cleared by the FDA in 2008, not 2006. This date is important because prior to FDA clearance, the AMDL "longs" used this argument to explain why global sales of DR-70 were so dismal prior to 2008: "the world won't start using DR-70 until it's cleared in the USA. As soon as the FDA clears DR-70, sales will skyrocket."
For anyone interested in doing real DD about this company, start here, in 1996:
http://www.thefreelibrary.com/AMDL+ANNOUNCES+EXCLUSIVE+DISTRIBUTION+AGREEMENT+FOR+DR-70%28TM%29+CANCER...-a018021957
Pay particular attention to this statement:
"Under the terms of the exclusive agreement, Brilliant International must make minimum revenue payments totaling US$5.3 million for the DR-70(TM) test kits on an established escalating annual schedule over the next five years."
This type of hype PR was repeated several times in the ensuing 15 years for various countries, always promising multi-million $$$ revenues, ending with the Guar Diagno distribution agreement of 2011.
None of the revenue predictions ever came close to being true.
Anyone doing serious DD on this company should read those PR's. And, pay special attention to what happened in Great Britain in 2000-2001.
here's a fact:
when this company was operating, their gross revenues never exceeded 5% of their FORECAST gross revenues. That's right, the CEO missed his guidance by 95% every time he gave guidance.
Here's another: this company defaulted on EVERY loan they took out after MacLellan became CEO.
Here's another: they haven't filed a financial report since 4th Qtr 2011.
Here's another: after MacLellan took over and Jade mutinied and the only income was from onko-sure, the highest annual gross revenue total was $314,000 (in 2011). Operating expenses were $10 million that year (not counting the debt). That is the best the company ever did from an operations standpoint: gross revenues about 10% of operating costs.
Another fact: If you add the other expenses, this company lost about $85 million per year the last two years it operated (2010 and 2011).
Anyone clamoring for some kind of resurrection of this company and/or DR-70 has to answer one important question: WHY? Biotech is all about profits and making money. A developmental biotech can burn cash like that because there is a CHANCE it will be profitable some day, but when it gets FDA clearance for its flagship product (as AMDL did in 2006), the CEO has to meet his guidance, or the company dies. This company is proof that a biotech cvan't just get FDA clearance -- it has to SELL something; and patents are worthless if the device is not profitable.
No evidence that GCDx is pursuing ANYTHING at the moment.
This is the kind of misinformation that runs rampant on the yahoo board.
Anyone who says GCDx is "pursuing" anything is misrepresenting the situation. There is no evidence that GCDx is anything more than a GoDaddy website and LLC registration.
GCDx was seeking funding from one Midwestern investor in 2012, but that investor backed out. There is no evidence that GCDx has done, or is doing, anything since October 2012.
Maybe Gartner is trying to get funding, maybe he is working solely for Provista, maybe he is building a sailboat in his back yard. Any conjecture about what he is doing now is just that - conjecture.
If it interests anyone, the current "rumor" being fanned on yahoo right now is this: Radient's lenders are converting debt to RXPC shares, then trading those shares to Provista private shareholders for their Provista shares, apparently in an attempt to take over Provista. Provista is also buying RXPC shares on the open market. Soon, Fortis/SRL is going to swoop down and buy Provista from the lenders, which will give them ownership of Radient too.
Read it again. I'm serious: that's the current Yahoo recipe for the buyout/merger rumor. think the underdawg blogger will spread THAT one?
LC Sentinel is a formulation of DR-70. They are not combined.
This is the kind of dangerous misinformation that is spread liberally on the yahoo board.
Read the BMR interview of MacLellan in which MacLellan clearly states that LC Sentinel is a formulation of DR-70.
Provista has since dropped LC Sentinel from their product line, without ceremony or explanation.
The most important thing about any medical drug or device is:
Will it generate enough revenues to be profitable?
DR-70 has proven that it does NOT generate enough revenues to be profitable. Forget the $85 million this company lost in 2010 and 2011 -- we all know what inflated those numbers. What is important is: When Radient *focused* on DR-70 sales, they could only generate about $330,000 annual gross revenues. They spend $8 million in annual operating costs to do that.
The numbers don't lie. DR-70 is a business failure. The global medical community tried DR-70 and rejected it.
That's why this company failed -- not because Feuerstein bashed it, or because the lenders sabotaged it. All MacLellan had to do to make Radient successful was sell DR-70. He tried, he failed, end of story, literally, END OF STORY.
I don't know why anyone is still talking about this company. Nobody wants the patents, nobody wants the test, and even if someone DID want the test they would license it for a few hundred thousand $$$ instead of merging with or acquiring Radient -- and a few hundred $$$ won't even pay the overdue utility bills.
There is no white knight. This is a zombie stock. SRL provided some hype and some pinksheet traders made some quick cash, but I don't see any more hype coming down the pike.
Insult me all you want - I don't care.
Intelligent investors will look at your words and look at mine and decide for themselves who is talking sense.
Have you tried spreading the "Fortis is buying Radient" rumor here on IHUB yet? They're just starting that one on Yahoo, after an intelligent investor pointed out that Provista said in an April SEC filing that they have no current plans for a merger.
If you disagree with what someone says, offer a counter-argument.
If you are unable to do so, attacking that person is an admission of that inability.
I said three posts ago that the pumptards would act this way. You are proving me right.
Why am I here? Because I don't like to see a public forum used to spread lies and deceit. I am not a basher. I speak only the truth. There is a difference.
jim, anyone could post those two messages on that public opinion forum -- the SAME PERSON could post those two messages. YOU could have posted those two messages.
You don't really think a doctor told "Tracy" that there will be a new DR-70 test "for all types of cancer," do you? Because that is absurd. Think about it. It's not even worth furthert discussion.
"Tracy" should have told "bonnie" to contact SRL in India.
"Still believe there are operations going on behind the scenes at Radient Pharmaceuticals."
Why? The company consists of two people: a CEO who has moved on to plastics manufacturing, and another guy (Boswell) who never did anything when the company was operating.
"but at the same time [the patent activity] shows that the business is not dead and that someone is keenly aware of important operations."
Patent renewal shows nothing other than someone is willing to spend a few hundred $$$ to keep patents alive.
"That's the new patent which will be effective for all types of cancer..."
The old patent was too.
"so really whomever gets FDA approval to manufacture kits..."
huh? you don't get FDA clearance to manufacture anything -- you get FDA clearance to SELL it. Anyone who did 10 minutes of DD knows that this company (AMDL) had a VERY hard time getting DR-70 cleared for sale as a CRC MONITORING test when they had CEA as a substantial equivalent, and it was only cleared for use in conjunction with CEA after two rejections. There is no substantial equivalent for LC. It will take a PMA.
"You can get a glimpse of how this works with the latest Global Cancer DX licensing for Lung Cancer."
A glimpse of WHAT? GCDx has no license for anything. They are a paper shell with a GoDaddy website and an LLC registration.
"Who knows whats going on now..."
Well finally, an honest statement, instead of the usual "we know there's a merger in progress," this blogger admits that there is no evidence of ANYTHING happening.
"In other countries like India, they are using Onko-Sure for all types of cancer. "
That is misleading to the point of absurdity. SRL Diagnostics is selling DR-70 for half price ($44) without the support of the Indian medical community or the Indian Government. Has this blogger heard of Guar Diagno?
"I don't think Radient will go bankrupt. They have operations and just not reporting anything, and most likely the share price will go back up on a probable upcoming favorable press release."
There is no evidence that Radient has "operations." SRL is selling old stock they bought in 2011. And Radient has no money for PR's -- they have been using 8K's as a poor man's PR.
This blogger does not know much about this company or the test they tried to sell. I use past tense because this company closed its doors in 2012 and MacLellan fired everyone else except his pal Boswell -- his partner responsible for running Edgewater Foods into bankruptcy and AXM Pharma into zombieland, where RXPC not resides.
I think the reason you brought RXPC to this message board is because you're pump-and-dump nonsense has been run off every other public forum.
Here's why Radient Pharmaceuticals is dead - quoted from the Yahoo board:
1. If an entity wanted to sell DR-70 or develop it for LC in the USA, they could license it for a few hundred thousand dollars. There is no reason to buy Radient and assume the $20 million debt.
2. Real biotechs don't start out on the pinksheets. Nobody wants to assume Radient's listing on the bottom rung of the pinksheets and bring those SEC financials up-to-date. Far better to do an IPO and start a new listing on the NASDAQ.
3. Nobody wants CIT. CIT hasn't been touched since the year 2000. Dr. Chang, its inventor, has been working on newer gene therapy and cancer vaccine technology since 2000. Anyone who .wants to invest in cancer vaccines would just hire Chang. Even Radient knew this when they hired Chang under NuVax.
4. Radient MAY have been a buyout/merger candidate in 2011 when they claimed $20 million equity in Jade on their balance sheet. But the SEC made Radient remove that equity from the balance sheet because it was false. Without that, Radient has little value to anyone.
5. MacLellan said in 2009 "we are focusing on selling DR-70," but by 2011, his best year of DR-70 sales, he still only managed $313,559 gross annual revenues, compared to $2.5 million operating costs per quarter. DR-70 has been on the global market since 1996 -- eventually a person has to admit that the global medical community does not want to use DR-70.
6. The $20 million debt is real. You might forgive a bad loan to your brother-in-law, but Radient's lenders are not going to forgive the defaulted loans. It's business. And default interest is accruing at over $4 million per year; do the math.
I challenge the resident "longs" to refute even ONE of those points and explain why any entity would want to acquire a toxic company like Radient. Notice how they will refuse to do so -- instead, they will attack me personally for posting this. Intelligent investors, decide for yourselves who is giving you the straight dope and who is pulling your leg.
The 5 million was based on the last SEC filing and that's all pinksheets.com can do.
I was thinking 15 billion.... that's 150 million post-split.
I sold for .014 Friday and was happy to get it. I think I'll buy back in at .002 and let it ride. I think the chances of BK are about 50% and FDA clearance about 50%. It's a race to see which comes first. I don't think we'll have to wait long -- within 3 months, one or the other will happen, IMO.
I already wrote this investment off at .0001 pre-split, so getting back in at .002 post-split is kind of a win. To a gambler. Which is what we all are, bottom-feeding in the pinksheets like this.
GLTA
If you think "FDA decision is any day now," you haven't read the 1/25/2011 shareholder letter. At that time, Davis said the FDA had asked questions that were not responded to yet. That means the FDA asked questions TWICE. Not good.
That also means the FDA needs to look at the next response before making a decision. So the FDA decision is at least 2 months away, IMO. Could be 6 months. The FDA doesn't have the ParaMax on a fast track, that's for sure. The question is, will Paradigm keep the doors open?
And if you think "FDA decision any day now" because of what some "experts" say on this message board, go back and read this message board from Dec 2009. Yes, 2009. The experts here were saying with certainty "FDA clearance any day now." Turns out the 510(k) hadn't even been submitted!
Thursday was pure manipulation, made possible by the fact that shareholders like me didn't have our new PDMID shares yet. Friday was people like me selling as soon as we got our new PDMID shares. Monday's selling was the old shareholders who weren't paying attention last week, or who didn't get their new shares until after market close Friday.
Friday, I said I'd buy back at .005. Today I'm thinking .002. When I buy back in, I'm accepting the possibility and perhaps even the inevitability of bankruptcy. I was OK with holding pre-split at .0001 because the pps just wasn't falling below that level, but I sold Friday because now there's plenty of room below.
From the volume since the split, I don't think there's any question that the O/S is much higher than 5 million. 100 mllion, is my guess. I haven't been reading the board but if anyone really knows the O/S, please repeat it. TIA
when I talked to the T/A many months ago, they told me they wouldn't give out that info -- I had to contact Paradigm.
Which I tried, without success.
this is a hard link to find now that the R/S shareholder letter is posted on paradigm's website...
but you should read this shareholder letter from Davis dated January 25, 2011:
http://www.paradigm-medical.com/Library/Shareholders_Ltr_012511.pdf
when that letter came out, pre-split shareholders like me said "oh well, it's probably lost money now, but it probably won't go below .0001."
Then the split happened. Retail investors liek me couldn't sell yesterday and we couldn't sell at market open today either... but around 9:00 central, suddenly we had our shares. If you look at a candle chart, you can see what happened then.
I have no doubt that I can buy this all back at .005 next week. The question is, do I want to. The FDA asked for more info mid-2010, and CSO responded (see Sept. 17th PR). ... now the FDA asked for MORE info, and as of January 25th, CSO had not responded yet, and Davis's shareholder letter has a defeated tone.
They could easily go bankrupt before the FDA clears the RetiMax. I consider all pinksheets to be gambling, but, this volume is manufactured -- this is manipulation.
GLTA
not a chance.
Read Davis' Shareholder Letter dated 01/25/2011:
http://www.paradigm-medical.com/Library/Shareholders_Ltr_012511.pdf
They are closer to bankruptcy than to retimax clearance, IMO.
something to consider:
I had 45 million shares at .0001 pre-split. I got sucked in here by the pump in December 2009. I've been averaging down for over a year.
The shareholder letter from Davis on the website in December has us "longs" concerned that the company could go BK at any moment, but, at .0001, it was pretty safe -- it wasn't dropping below that line.
None of us know what the O/S really was, because the transfer agent wouldn't say. But I'm pretty sure the current float is higher than 5 million, post split.
When they did the R/S yesterday, I thought "oh crap, now there's plenty of room below, it's going to .0005 in a heartbeat." But I didn't have my PDMID shares in TDA yesterday. Many retail investors like me couldn't sell yesterday.
Well, this morning, around 9:30, I got my new shares -- 450,000 of them -- and I've been selling for whatever I can get.
The price went high yesterday because there weren't many shares available, IMO. Different story today. I think we all got our new PDMID shares at the same time.
I think I'll be able to buy this back next week at .005. Just my opinion. I realize that you momo players don't plan on holding this stock through the weekend, so you don't care. I'm just saying: if you think there are a lot of shares available today -- I think I know why.
GLTA
Who really knows what the O/S was pre-split?
The bashers were saying 11 billion, but I could never verify. WHO verified, and could someone post a link?
I'm in the same boat with TDA
I didn't even read the PR today after seeing the date...
But now I see that CSO is also the manufacturer of the two products they introduced. Interesting.
As I stated last week... proxy votes are often preceded by news. I expect more news before Friday. This 2-month-old PR we got today was already known.
The FDA clearance will be for Retimax, not Paramax, I believe. If Paradigm is slow to release news, we could see it on the FDA website first, if clearance is granted.
GLTA
I know what ParaMax is! It's RetiMax - referenced in the 10Q and in the April PR about the distribution partnership with CSO (Italian), the maker of RetiMax.
Go to the CSO website, click on "News," and be serenaded by Elvis! Funny!
I feel that a burden has been lifted. I tried very hard to DD ParaMax and could not find it -- and therefore doubted its existence -- but now it seems obvious!
CSO stands for CSOpthalmic, sort of. CSO Strumenti Oftalmici, apparently.
Here's an abstract. my fiance is a college prof so she can get me the article but not tonight.
http://www.iovs.org/cgi/content/full/49/3/1151
Still looking for information about who submitted the 510(k), who helped them, and when.
docgreen,
thanks for the response.
My experience with proxy votes is: The company tends to release news BEFORE the vote, not after.
I've been investing in developmental biotechs for over 10 years. This is my first experience with a 510(k) that was kept secret until clearance. I've seen some unethical and even criminal behavior from CEO's in this sector, so I find it prudent to be cynical and miss some windfalls as opposed to buying everything I see that looks shiny.
I own PDMI and I plan to buy more -- but I would like to know exactly what ParaMax is. My understanding of Paravue is, they needed more $$$ to assemble and file the 510(k), so I'm puzzled about where the money came from to file an FDA app for ParaMax.
Secret devices? Cloak and dagger? Very unusual. Do we even know if ParaMax is a Class II or Class III device?
The CEO will freely tell anyone over the phone about ParaMax, but won't mention it in the 10Q, in a PR, or on their website? No news about trials, test results... no posters or presentations at conferences.... Very Unusual.
GLTA
Let's sumamrize. you say that the CEO of Paradigm would never talk to a shareholder. I disagree.
I work in the IS Department for an insurance company that employs over 3000 people in the Home Office. Our CEO talks to people all the time. That is basically what he does. He does NOT talk to jobbers and contractors. That is my point and I'm sorry I didn't make it clearer.
You call me immature and call me "son" -- I guess you think that establishes your ethos. Suggestion: if you want to establish ethos, use a spell-checker.
GLTA
I've spoken with CEO's of much larger developmental biotechs than Paradigm. What kind of company is yours? I'm guessing that you are much busier than these CEO's.
Unless you're a CEO of a developmental biotech yourself? Maybe that's your point. In which case, I have to ask, how can you have time to post on stock message boards but no time to talk to shareholders?
This is a funny board. Seems like everyone is taking Paramax for granted as an actual product, but fears a reverse split and dilution.
R/S and dilution is the best way for a developmental biotech to get funding. The alternative is usually a loan at usurious rates.
I would welcome a 100:1 R/S to bring the pps to 30 cents. And increasing the authorized shares doesn't concern me either.
What concerns me is the suspicion that "ParaMax" is a figment of someone's imagination. If the company is on the verge of getting 510(k) clearance for a device, they must have submitted the application in August... so why no mention of ParaMax in the guidance that accompanied the last 10Q?
new to Ihub, but not to PDMI. I own a few million shares and am considering buying more.
I want to know why I cannot find ANYTHING about "Paramax" except on this Ihub message board?
I've been trying to call the company but they rarely answer the phone. the one time a guy answered, he seemed flustered and then said "That's a question for Stephen Davis." Mr. Davis was supposed to call me back but never did.
Sterling, what is Paramax? The company has never mentioned this product/device and it's not mentioned in any PR or news article... it wasn't mentioned in the guidance in August.... What is it?
TIA